Description:
The viral vectors market is evolving with advancements in gene therapy and vaccine technologies. New developments are enabling viral vectors to produce stable, non-toxic, and safe therapeutic outcomes. As the industry moves towards standardized and automated manufacturing processes, the potential for viral vectors in treating cancers, genetic diseases, and other conditions continues to grow. Kalorama Information covers this market in the new report Viral Vectors Market for Cell Therapy Market Analysis and Opportunities, 2021-2026.
By the middle of the decade, viral vectors are expected to experience significant growth. This should not be surprising. Globally, millions of dollars are invested annually in viral vector technology for gene therapy and vaccines. In 2021, sales of viral vectors reached impressive figures, reflecting their crucial role in modern medicine. The rise of gene therapy and novel vaccine technologies has been a significant game changer in this market.
Updated for COVID-19 Impacts
In some segments, COVID-19 caused a contraction due to lockdowns, closures, limited physician visits, and a reduction in elective and outpatient procedures. However, the market is expected to resume pre-pandemic growth across all segments. Certain areas will continue to advance significantly from 2021-2026. By 2026, the total global viral vectors market is projected to reach new heights, displaying robust growth over the forecast period.
Market Breakdown
- Global Viral Vectors Market, 2021-2026 (in millions $ at manufacturer level)
- Global Viral Vectors Market Analysis by Product Category, 2021 (in millions $) (Gene Therapy, Vaccines, Total)
- Global Gene Therapy Viral Vectors Market Analysis by Product Category, 2021 (in millions $) (Retroviruses, Adenoviruses, Lentiviruses, Others, Total)
- Global Vaccine Viral Vectors Market Analysis by Product Category, 2021 (in millions $) (Adenoviruses, Poxviruses, Alphaviruses, Others, Total)
Regional Market Analysis
The viral vectors market is also segmented by geographic region:
- Global Viral Vectors Market Analysis by Region/Country, 2021 (in millions $) (United States, Europe, Japan, ROW, Total)
- European Viral Vectors Market Analysis by Country, 2021 (in millions $) (Germany, UK, France, Italy, Others, Total)
- Asia-Pacific Viral Vectors Market Analysis by Country, 2021 (in millions $) (China, Japan, South Korea, India, Australia, Others, Total)
Segment Size and Growth
Viral vector technology has significantly contributed to the growth of the overall gene therapy and vaccine markets over the past decade. More manufacturers are seeking regulatory approvals and expanding their capabilities. As new technologies emerge, viral vectors are expected to play an even more significant role in therapeutic development and patient care. The report provides an in-depth analysis of various market segments, including:
- Global Gene Therapy Viral Vectors Market Analysis, 2021-2026 (in millions $ at manufacturer level)
- Global Vaccine Viral Vectors Market Analysis, 2021-2026 (in millions $ at manufacturer level)
Scope and Methodology
All market data are based on manufacturer sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers’ level. The base year for data was 2021 with forecast data provided for 2026. Compound annual growth rates (CAGRs) are provided for the 2021-2026 period for each segment covered. The forecasted market analysis is largely based on demographic trends, new developments, cell and gene therapy advancements, company performance trends, mergers and acquisitions, and global expansion.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
